$ABAT·8-K

AMERICAN BATTERY TECHNOLOGY Co · Jul 10, 4:45 PM ET

Compare

AMERICAN BATTERY TECHNOLOGY Co 8-K

Research Summary

AI-generated summary

Updated

American Battery Technology Co. Re-signs CEO, CFO, COO with New Pay Packages

What Happened

  • American Battery Technology Company (ABAT) filed an 8-K reporting new two‑year employment agreements, effective July 1, 2026, with CEO Ryan Melsert, CFO Alejandro Flores Arteaga, and COO Steven Wu to continue in their roles.
  • Key pay terms: annual salaries of $475,000 (CEO), $280,000 (CFO) and $350,000 (COO); each executive is eligible for performance‑based bonuses (annual cash bonus target = 75% of salary), RSU awards, and stock options tied to milestone achievement. The Compensation Committee approved the agreements after a market assessment and intends them to be exempt under Section 16b-3.

Key Details

  • Effective date and term: July 1, 2026 — two‑year term for each agreement.
  • Cash salary and bonus: CEO $475,000; CFO $280,000; COO $350,000. Annual cash bonus target = 75% of salary (performance‑based, pro‑rated by milestone weighting).
  • Equity grants:
    • RSUs: CEO 1,000,000; CFO 500,000; COO 750,000 (calculated using the 20‑day VWAP prior to July 1, 2026).
    • Stock options: CEO 3,000,000; CFO 1,000,000; COO 1,500,000 at an exercise price of $2.76/share (closing price on July 1, 2026).
  • Vesting and expirations: FY2027 RSUs and options vest 1/16th quarterly beginning July 1, 2026 (options expire July 1, 2036); FY2028 RSUs and options vest 1/16th quarterly beginning July 1, 2027 (options expire July 1, 2037).
  • Total potential equity awarded (maximum figures disclosed): 2,250,000 RSUs and 5,500,000 stock options across the three executives.

Why It Matters

  • These agreements confirm retention of ABAT’s top executives and align their pay with performance milestones, which can affect company strategy execution and continuity.
  • The equity awards and options create potential future dilution if exercised or settled as RSUs; investors should note the grant sizes, exercise price ($2.76), and multi‑year vesting schedule when assessing shareholder dilution risk and management incentives.
  • Because bonuses and a large portion of compensation are performance‑based, the actual cash and equity cost to the company will depend on future achievement of strategic milestones (amounts may be pro‑rated per milestone).